Literature DB >> 25047979

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

Naval Daver1, Aditi Shastri1, Tapan Kadia1, Kate Newberry1, Naveen Pemmaraju1, Elias Jabbour1, Linghsa Zhou1, Sherry Pierce1, Jorge Cortes1, Hagop Kantarjian1, Srdan Verstovsek2.   

Abstract

We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin < 10 g/dL). Patients (n = 29; 18 RBC-transfusion dependent) received 0.5mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270. Published by Elsevier Ltd.

Entities:  

Keywords:  Anemia; Myelofibrosis; Pomalidomide

Mesh：

Substances：

Year:  2014        PMID： 25047979      PMCID： PMC4157096          DOI： 10.1016/j.leukres.2014.06.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  21 in total

1.  Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.

Authors:  Francisco Cervantes; Alberto Alvarez-Larrán; Abel Domingo; Eduardo Arellano-Rodrigo; Emili Montserrat
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

2.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Authors:  Ayalew Tefferi; Jorge Cortes; Srdan Verstovsek; Ruben A Mesa; Deborah Thomas; Terra L Lasho; William J Hogan; Mark R Litzow; Jacob B Allred; Dan Jones; Catriona Byrne; Jerome B Zeldis; Rhett P Ketterling; Rebecca F McClure; Francis Giles; Hagop M Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

Review 3.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Authors:  Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

4.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.

Authors:  Ruben A Mesa; Joyce Niblack; Martha Wadleigh; Srdan Verstovsek; John Camoriano; Sunni Barnes; Angelina D Tan; Pamela J Atherton; Jeff A Sloan; Ayalew Tefferi
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

5.  Thalidomide therapy for myelofibrosis with myeloid metaplasia.

Authors:  Deborah A Thomas; Francis J Giles; Maher Albitar; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Susan M O'Brien; Guillermo Garcia-Manero; Michael J Keating; Sherry Pierce; Jerome Zeldis; Hagop M Kantarjian
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

6.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

Review 7.  The chronic myeloproliferative disorders: clonality and clinical heterogeneity.

Authors:  Jerry L Spivak
Journal:  Semin Hematol       Date:  2004-04       Impact factor: 3.851

8.  Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Authors:  Monia Marchetti; Giovanni Barosi; Francesca Balestri; Gianluca Viarengo; Sara Gentili; Sara Barulli; Jean-Loup Demory; Fiorella Ilariucci; Antonio Volpe; Dominique Bordessoule; Alberto Grossi; Marie Caroline Le Bousse-Kerdiles; Andrea Caenazzo; Alessandro Pecci; Antonietta Falcone; Giorgio Broccia; Cesarina Bendotti; Fredric Bauduer; Francesco Buccisano; Brigitte Dupriez
Journal:  J Clin Oncol       Date:  2004-02-01       Impact factor: 44.544

9.  A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Authors:  Ruben A Mesa; David P Steensma; Animesh Pardanani; Chin-Yang Li; Michelle Elliott; Scott H Kaufmann; Gregory Wiseman; Leigh A Gray; Georgene Schroeder; Terra Reeder; Jerome B Zeldis; Ayalew Tefferi
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

Review 10.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin
Journal:  Semin Radiat Oncol       Date:  2003-07       Impact factor: 5.934
View more
  20 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 2.  Management of Myelofibrosis-Related Cytopenias.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 3.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

4.  Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.

Authors:  Ting Liu; Feng Guo; Xiaomin Zhu; Xiangge He; Lin Xie
Journal:  Exp Ther Med       Date:  2017-09-27       Impact factor: 2.447

5.  Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Authors:  R F Schlenk; F Stegelmann; A Reiter; E Jost; N Gattermann; H Hebart; C Waller; A Hochhaus; U Platzbecker; P Schafhausen; I W Blau; W Verbeek; F H Heidel; M Werner; H Kreipe; V Teleanu; A Benner; H Döhner; M Grießhammer; K Döhner
Journal:  Leukemia       Date:  2016-10-24       Impact factor: 11.528

Review 6.  Myelofibrosis: an update on drug therapy in 2016.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

Review 7.  Pharmacotherapy of Myelofibrosis.

Authors:  Douglas Tremblay; Bridget Marcellino; John Mascarenhas
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

8.  Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.

Authors:  Naval Daver; Jorge Cortes; Kate Newberry; Elias Jabbour; Lingsha Zhou; Xuemei Wang; Sherry Pierce; Tapan Kadia; Koji Sasaki; Gautam Borthakur; Farhad Ravandi; Naveen Pemmaraju; Hagop Kantarjian; Srdan Verstovsek
Journal:  Haematologica       Date:  2015-06-18       Impact factor: 9.941

Review 9.  Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.

Authors:  Julian A Waksal; John Mascarenhas
Journal:  Curr Hematol Malig Rep       Date:  2022-08-19       Impact factor: 4.213

Review 10.  JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

Authors:  Andrew T Kuykendall; Rami S Komrokji
Journal:  J Immunother Precis Oncol       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.